Edition:
United Kingdom

Bausch Health Companies Inc (BHC.TO)

BHC.TO on Toronto Stock Exchange

30.98CAD
18 Apr 2019
Change (% chg)

$0.21 (+0.68%)
Prev Close
$30.77
Open
$30.91
Day's High
$31.19
Day's Low
$30.36
Volume
1,020,694
Avg. Vol
981,477
52-wk High
$36.52
52-wk Low
$21.39

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals Confirms Bausch Health As Successful Bidder For Its Business Assets
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS CONFIRMS BAUSCH HEALTH AS SUCCESSFUL BIDDER FOR ITS BUSINESS ASSETS.SYNERGY PHARMACEUTICALS - CURRENTLY EXPECTS AGREEMENT WITH BAUSCH HEALTH WILL BE APPROVED BY BANKRUPTCY COURT ON MARCH 1, 2019.  Full Article

Bausch Health Companies Acquires Eton Pharmaceuticals' EM-100 Investigational Eye Drop
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH ACQUIRES ETON PHARMACEUTICALS' EM-100 INVESTIGATIONAL EYE DROP FOR THE TREATMENT OF ITCHY EYES ASSOCIATED WITH ALLERGIES.BAUSCH HEALTH COMPANIES INC - EM-100 HAS BEEN SUBMITTED TO FDA FOR REVIEW.  Full Article

Bausch Health Says Expects To Commence Sales And Marketing Of Vyzulta In Canada In Q2 2019
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH'S CANADIAN BUSINESS POSITIONED FOR GROWTH IN 2019.BAUSCH HEALTH COMPANIES INC - BAUSCH HEALTH EXPECTS TO COMMENCE SALES AND MARKETING OF VYZULTA IN CANADA IN Q2 2019.  Full Article

Bausch+Lomb Announces Health Canada Approval Of Vyzulta For Treatment Of Glaucoma
Thursday, 3 Jan 2019 

Jan 3 (Reuters) - Bausch Health Companies Inc ::BAUSCH + LOMB ANNOUNCES HEALTH CANADA APPROVAL OF VYZULTA™ (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION, 0.024%) FOR THE TREATMENT OF GLAUCOMA.BAUSCH HEALTH COMPANIES - ON DECEMBER 27, 2018, HEALTH CANADA ISSUED NOTICE OF COMPLIANCE FOR VYZULTA.  Full Article

Bausch Health To Seek Incremental Amendment To Its Existing Credit Agreement
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Bausch Health Companies Inc ::BAUSCH HEALTH TO SEEK INCREMENTAL AMENDMENT TO ITS EXISTING CREDIT AGREEMENT.BAUSCH HEALTH - UNIT EXPECTED TO BORROW $750 MILLION OF NEW TERM B LOANS UNDER CREDIT AGREEMENT.BAUSCH HEALTH - INTENDS TO HAVE UNIT ISSUE $750 MILLION OF SECURED DEBT SECURITIES.BAUSCH HEALTH - NET PROCEEDS, WITH CASH ON HAND, EXPECTED TO BE USED TO REFINANCE OUTSTANDING 7.500% SENIOR NOTES DUE 2021.  Full Article

Progenics Pharma says Co, Valeant Pharma, Salix Pharma, Wyeth, Actavis Entered Settlement And License Agreement
Thursday, 31 May 2018 

May 31 (Reuters) - Progenics Pharmaceuticals Inc ::PROGENICS PHARMACEUTICALS - ON MAY 25, CO, VALEANT PHARMACEUTICALS, SALIX PHARMACEUTICALS, WYETH, ACTAVIS ENTERED SETTLEMENT AND LICENSE AGREEMENT.PROGENICS PHARMACEUTICALS - THE SETTLEMENT AND LICENSE AGREEMENT IS RELATING TO TWO ACTIONS FOR PATENT INFRINGEMENT IN U.S. DISTRICT COURT -SEC FILING.  Full Article

Valeant Receives Health Canada Approval Of Siliq (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Wednesday, 14 Mar 2018 

March 14 (Reuters) - Valeant Pharmaceuticals International Inc ::VALEANT RECEIVES HEALTH CANADA APPROVAL OF SILIQ (BRODALUMAB) FOR MODERATE-TO-SEVERE PLAQUE PSORIASIS.VALEANT CANADA SAYS EXPECTS TO COMMENCE SALES AND MARKETING OF SILIQ IN THE CANADA IN THE SECOND HALF OF 2018.  Full Article

Valeant Announces Launch Of Private Offering Of Senior Notes
Monday, 12 Mar 2018 

March 12 (Reuters) - Valeant Pharmaceuticals International Inc ::VALEANT ANNOUNCES LAUNCH OF PRIVATE OFFERING OF SENIOR NOTES.  Full Article

Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
Monday, 12 Mar 2018 

March 12 (Reuters) - Valeant Pharmaceuticals International Inc ::VALEANT AND ONE OF ITS SUBSIDIARIES COMMENCE CASH TENDER OFFERS FOR UP TO $1,250,000,000 OUTSTANDING PRINCIPAL AMOUNT.VALEANT - ‍TENDER OFFERS FOR NOTES WILL EXPIRE ON APRIL 9, 2018​.  Full Article

Valeant's LT goals on new launches, dermatology pipeline "unrealistic"-Piper
Tuesday, 6 Mar 2018 

March 5 (Reuters) - Valeant VRX.N::PIPER JAFFRAY SAYS MANAGEMENT'S LONGER-TERM ASPIRATIONAL GOALS FOR NEW LAUNCHES AND DERMATOLOGY PIPELINE ARE "UNREALISTIC".PIPER SAYS INSUFFICIENT DIFFERENTIATION, AVAILABILITY OF GENERICS, BRAND COMPETITION, HEAVY PAYER CONTRACTING RENDER LONGER-TERM TARGETS UNREALISTIC.  Full Article

U.S. FDA loosens alcohol restrictions for female libido pill

April 11 The U.S. Food and Drug Administration said on Thursday women taking Sprout Pharmaceuticals Inc's female libido pill, Addyi, need not completely avoid alcohol.